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O-GlcNAc Transferase (OGT) catalyzes protein O-GlcNAcylation, an abundant and dynamic
nuclear and cytosolic modification linked to epigenetic regulation of gene expression. The
steady-state levels of O-GlcNAc are influenced by extracellular glucose concentrations
suggesting that O-GlcNAcylation may serve as a metabolic sensor. Intriguingly, human
OGT is located on the X-chromosome (Xq13) close to the X-inactivation center (XIC),
suggesting that OGT levels may be controlled by dosage compensation. In human female
cells, dosage compensation is accomplished by X-inactivation. Long noncoding RNAs and
polycomb repression act together to produce an inactive X chromosome, or Barr body.
Given that OGT has an established role in polycomb repression, it is uniquely poised
to auto-regulate its own expression through X-inactivation. In this study, we examined
OGT expression in male, female and triple-X female human fibroblasts, which differ in
the number of inactive X chromosomes (Xi). We demonstrate that OGT is subjected to
random X-inactivation in normal female and triple X cells to regulate OGT RNA levels. In
addition, we used chromatin isolation by RNA purification (ChIRP) and immunolocalization
to examine O-GlcNAc levels in the Xi/Barr body. Despite the established role of O-
GlcNAc in polycomb repression, OGT and target proteins bearing O-GlcNAc are largely
depleted from the highly condensed Barr body. Thus, while O-GlcNAc is abundantly
present elsewhere in the nucleus, its absence from the Barr body suggests that the
transcriptional quiescence of the Xi does not require OGT or O-GlcNAc.
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INTRODUCTION
O-GlcNAc is an abundant and dynamic modification found
on approximately 4000 nuclear and cytoplasmic proteins (Ma
and Hart, 2014). This post-translational modification (PTM)
is added to serine and threonine moieties by O-GlcNAc trans-
ferase (OGT) and affects various cellular functions includ-
ing protein stability, transcriptional activity and intracellular
localization. OGT utilizes the end product of the hexosamine
biosynthetic pathway, UDP-GlcNAc to transfer a single N-
acetylglucosamine onto proteins. With 2–3% of intracellular
glucose contributing to the hexosamine biosynthetic pathway,
OGT is able to sense cellular glucose intake (Marshall et al.,
1991) and coordinates an appropriate cellular response by mod-
ifying transcription factors, kinases, nuclear pore proteins and
RNA Polymerase II. This modification is reversible as a sec-
ond enzyme, O-GlcNAcase (OGA), removes the GlcNAc residue.
Through dynamic O-GlcNAc cycling, OGT and OGA trans-
form this single PTM into a metabolic sensor (Hanover et al.,
2010). After discovery of the O-GlcNAc modification (Torres and
Hart, 1984), characterization of the enzymes (Braidman et al.,
1974; Haltiwanger et al., 1992), and identification of the cDNA
encoding OGT (Kreppel et al., 1997; Lubas et al., 1997) the
gene was localized to the X-chromosome in mice (XqD) (Shafi
et al., 2000) and humans (Xq13) (Hanover, 2001). Knowing
that OGT is an X-linked gene raises the question of how males
(XY) and females (XX) might differentially regulate their OGT
levels.
Dosage compensation is the process that equalizes female
and male sexual chromosome transcription. In mammals, dosage
compensation is accomplished by inactivation of one X chromo-
some in female cells through a process termed X-inactivation.
This mechanism was discovered in 1961 and is now well char-
acterized (Lyon, 1961). Although the majority of X-inactivation
studies have been performed using mice, the process is gen-
erally accepted to be similar for humans. During the early
stages of embryogenesis, the inner cell mass of the embryo has
two active X-chromosomes (Patrat et al., 2009) and undergoes
X-inactivation by first “counting” to define how many chromo-
somes need to be inactivated (Gartler and Riggs, 1983). Next,
all X-chromosomes but one are chosen for inactivation in a ran-
dom fashion (Beutler et al., 1962). X-inactivation continues with
the synthesis of the long non-coding RNA (lncRNA) XIST by
the X-inactivation Center (XIC) of the future inactivated chro-
mosome (Brown et al., 1991; Clemson et al., 1996). XIST RNA
spreads along the chromosome creating a landing platform for
recruitment of Polycomb Group (PcG) Repressive complexes
(PRC1 and PRC2) (Plath et al., 2003; De Napoles et al., 2004) that
deposit repressive histone modifications. Finally, the silencing is
maintained by gene promoter DNA methylation (Blewitt et al.,
2008). During this process, the inactivated X (Xi) is relocalized to
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a special nuclear structure called the Barr body (Barr and Bertam,
1949) characterized by high levels of silencing DNA marks and
heterochromatin.
X-inactivation is required for female development as deletion
of the mouse Xist locus, and thus the subsequent cascade of
silencing, is lethal for female embryos (Marahrens et al., 1997).
Additionally, presence of an Xi is also necessary for normal
female development as Turner syndrome patients (XO) exhibit
pathologic changes attributed to the presence of only a single X
chromosome (Bakalov et al., 2009). These pathologies are largely
attributed to X-linked genes that escape X-inactivation. Thus,
a number of genes along the Xi remain transcriptionally active
despite their location.While mice have proven to be a goodmodel
for many human diseases, studies of XO mice have largely been
unable to recapitulate phenotypes of Turner syndrome patients
(Disteche, 1999). Whereas around 15% of genes on the Xi escape
X-inactivation in humans, only about 3% escape in mice. Add-
itionally, there can be spatiotemporal regulation of Xi that may
occur for individual genes (Carrel and Willard, 2005; Yang et al.,
2010). Therefore, it is important to understand the X-inactivation
status of individual genes in human tissues in order to understand
the impact of gene dosage on human health and disease.
Intriguingly, it has been demonstrated that the timing of
silencing of X-linked genes corresponds to their proximity to
the XIC. Genes located close to the XIC are silenced earlier in
development than those farther away. Possibly due to its close
proximity to the XIC (Shafi et al., 2000), Ogt exhibits monoallelic
expression in differentiated mouse embryonic stem cells, a devel-
opmental time point where most X-linked genes are still bialleli-
cally expressed (Lin et al., 2007). Even though the X-inactivation
status of OGT has not been investigated in humans, indirect
evidence suggests that OGT silencing is required in humans
for normal health. It has been reported that DNA demethyla-
tion associated with lupus, an autoimmune disease predomi-
nantly affecting females, triggers or worsens disease development
(Hewagama et al., 2013). The authors reported that lupus flares
correlated with a hypomethylatedOGT promoter and an increase
in OGT levels (Hewagama et al., 2013).
Several studies have demonstrated an association between
OGT and the PcG proteins, a group of proteins integral to the
X-inactivation mechanism (Plath et al., 2003; De Napoles et al.,
2004), suggesting that OGT could be regulating its own expres-
sion. The homeotic gene Super sex combs (Sxc) in Drosophila
encodes OGT and is required for PcG group function (Sinclair
et al., 2009). Additionally, O-GlcNAc is abundant at PcG-binding
sites on polytene chromosomes (Gambetta et al., 2009). Finally,
PRC2 is tightly linked to OGT levels in mouse embryonic stem
cells (Myers et al., 2011). Therefore, OGTmight act through poly-
comb to influence its ownX-inactivation, thus creating a feedback
regulatory loop. In addition, O-GlcNAc may play a role in the
transcriptional silencing associated with the Barr body, hosting
the Xi. Here, we examined OGT expression in male, female and
triple-X female human fibroblasts, all of which have different X-
inactivation statuses. We demonstrate that OGT is subjected to
X-inactivation in female and triple-X cells to normalize OGT lev-
els. We were surprised to find that the Barr body, containing the
Xi, is substantially depleted of both O-GlcNAc and OGT relative
to other intranuclear locations. This suggests that high levels of
O-GlcNAc are not associated with the transcriptionally silenced
Xi in the Barr body.
MATERIALS AND METHODS
CELL CULTURE
GM00254 (47, XXX), GM00468 (46, XY) and GM6111 (46,XX)
cell lines were purchased from the NIGMS Human Genetic
Mutant Cell Repository and grown according to the recom-
mended conditions.
DRUGS AND RNAi
5-azacytidine was used at 10µM (Sigma Aldrich®), incubated
overnight in optiMEM and then for 2 days in classic cell culture
medium. Thiamet-G was used at 100 nM, azaserine at 5µM, both
for 2 h in fresh medium. XIST RNAi was purchased fromOrigen®
and used according to the recommended protocol. Briefly, cells
were transfected either with XIST or scrambled, control RNAi
using lipofectamine RNAimax (Invitrogen®). Cells were incu-
bated overnight in optiMEM medium and then for 2 days in
classic culture medium.
RT-PCR AND QUANTITATIVE RT-PCR (qRT-PCR)
Cells were washed twice with PBS and then trypsinized for 5min
at room temperature. Cells were then washed twice with PBS and
total RNAs were purified with RNeasy minikit (Qiagen®), includ-
ing a DNAse step, and recovered in 20µL of PCR-grade water.
RNA concentration was measured using the nanodrop dosage
spectrophotometer, and quality was checked by running RNA on
an agarose gel and analyzing the integrity of ribosomal RNA (28S
and 18S). Four micro litter of qScript cDNA Supermix (Quanta
bioscience) was added to 500µg of RNA extract and run on
a thermocycler to provide cDNA using the following program:
25◦C/5min; 42◦C/30min; 85◦C/5min: 10◦C/8. Total cDNA was
then quantified using nanodrop spectrophotometer.
For classic RT-PCR, 1µg of cDNA was mixed with 1µL
of ampliTaq DNA polymerase (5U/µL, Applied biosystems®),
0.5µL of each primer (100µM), 25µL of failsafe PCR 2x pre-
mix (Epicenter®) (in 50µL PCR grade water). Amplification
was performed on a thermocycler using the following pro-
gram: 95◦C/3min; 95◦C/1min; 85◦C/5min: (Primer hybridiza-
tion temperature)/1min; 72◦C/1min/kb (repeat three last steps
40×); 72◦C/2min; 4◦C/8. Finally, samples were run on 2%
agarose E-gel (Invitrogen).
For qRT-PCR, 1µg of cDNA was mixed with 10µL of fast
SYBR Green master mix (Applied Biosystems®) and 0.5µL of
each primer (100µM) (in 20µL PCR-grade water) and amplified
on AB 7900HT fast real time PCR system (Applied biosystems).
Each experiment was performed in triplicate, analyzed by cal-
culating the 2−CT (Livak and Schmittgen, 2001) relative to
actin expression and significance was calculated with the one-way
ANOVA test (GraphPad Prism v.6).
PRIMERS
Actin Ex-Ex (Exon-Exon junction): For (5′→3′) CCTT
CCTTCCTGGGCATGGAGT CC; Rev (5′→3′) GGAG
GAGCAATGATCTTGATCTTCC. G6PD intron: For
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(5′→3′): GGCATCAGCAAGACACTCTCTCC; Rev (5′→3′)
ACCCCATAGCCCACAGGTAT GC. OGT intron: For
(5′→3′) AGTTGTTATCTTTTGTATTACA; Rev (5′→3′)
AATTTGTTCAAGGAAAAGTTTACTTA. OGT Ex-Ex: For
(5′→3′) GGTGACTATGC CAGGAGAGACTCTTGC; Rev
(5′→3′) CGAACTTTCTTCAGG TATTCTAGATC. XIST Ex-Ex:
For (5′→3′) GGCTCCTCTTGGACATTCTGAGC; Rev (5′→3′)
CTTCTGAGGAAGATCTTTTTCTCC.
RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH)
Cells were cultured on 2-chamber-glass-slides (Electron
Microscopy Sciences) for one day. One hour before fixation,
fresh medium was added to the chamber-glass-slides. Slides were
then treated according the multiplex fluoresent assay RNAscope®
(Advanced Cell Diagnostics) protocol. Briefly, cells were washed
twice with PBS and then incubated for 10min at RT with 10%
Neutral Buffered Formalin (NBF) (10% Formaldehyde, 30mM
NaH2PO4, 45mM Na2HPO4). After two PBS washes, cells were
dehydrated successively in 50, 70, and 100% ethanol for 1min
each. Finally, cells were incubated in fresh 100% ethanol for
10min at RT. Cells were then rehydrated successively in 70%
ethanol, 100% ethanol and finally in PBS for 1min each at RT.
Finally, cells were incubated in fresh PBS for 10min at RT. Cells
were then treated with pretreat3 solution (RNAscope® pretreat-
ment Kit –FL FF, Advanced Cell diagnostics), containing protease
for 10min at RT. After two PBS washes, cells were incubated
with Human XIST lncRNA/OGT pre-mRNA mixed probe or
Human 2-plex-postive control probe (containing PPIB and
RNA polymerase II mRNA probes) or Human 2-plex-negative
control probe (containing two bacterial mRNA probes) for 3 h
at 40◦C. Probe detection was performed following the detection
kit protocol provided by Advanced Cell Diagnostics (RNAscope®
Detection Kit –FL). Finally, cells were mounted in DAPI/fluo-
romount G (Electron Microscopy Sciences). After drying, slides
were observed under a confocal microscope (Zeiss LSM700).
IMMUNOFLUORESCENCE
Cells were cultured on 2-chamber-glass-slides (Electron
Microscopy Sciences) for two days. Cells were then washed
twice with PBS and fixed in freshly made 1% paraformaldehyde/
PBS for 15min at room temperature. After three PBS washes
(5min each), cells were permeabilized at 4◦C for 15min in 1%
triton-X100/PBS. After three PBS washes (5min each), slides
were saturated in a 1% BSA/PBS solution for 15min at room
temperature and incubated with antibodies diluted at 1:200
in 1% BSA/PBS for 1h at room temperature. After three PBS
washes (5min each), cells were incubated with alexa-fluor 488
anti-mouse IgG or 568 anti-rabbit IgG secondary antibodies
(Life Technologies) diluted at 1:500 in 1% BSA/PBS for 30min at
room temperature and in the dark. Finally, cells were washed in
PBS three times and mounted in DAPI/fluoromount G (Electron
Microscopy Sciences). After drying, slides were observed under a
confocal microscope (Zeiss LSM700).
CHROMATIN ISOLATION BY RNA PURIFICATION (ChIRP)
ChIRP was carried out as previously described (Chu et al.,
2011). Briefly, 22 probes were designed to recognize the
human XIST RNA fragment from 10.5 to 13.5 kb (using www.
singlemoleculefish.com). Each probe was 20 bp in length and sep-
arated from the next by at least 80 bp (1 probe/100 bp). Probes
were numbered following the sequence from 1 to 22 and then
separated in 2 pools (odd and even), which were used as internal
controls for each other. Specific RNA and DNA content should be
found in both pools. Anti-sense DNA probes were labeled with a
3′-end BiotinTEG.
Cells were washed twice with PBS and then trypsinized at
room temperature (RT) for 5min. Cells were again washed twice
with PBS, cross-linked at RT for 10min in 400µL of 1% glu-
taraldehyde/PBS and then quenched by 400µL cold glycine at
250mM (final concentration 125mM) for 5min at 4◦C. After
centrifugation at 4◦C for 5min at 2500 rcf, and two PBS-washes,
pellets were resuspended in lysis buffer (10× mass pellet in
grams) [50mM Tris-Hcl pH 7, 10mM EDTA pH8, 1% SDS,
protease inhibitors (Roche)] with freshly added 1mM of PMSF
(Fluka) and Superase-in (Ambion). Lysate was sonicated (water
bath-sonicator) at 4◦C for at least 30min (30 s ON, 45 s OFF,
output 7) or until the sample was no longer turbid. After cen-
trifugation at 20,000 rcf for 10min, supernatant was kept for
ChIRP. After putting aside samples for DNA and RNA input,
lysates were diluted in 2 volumes of hybridization buffer (50mM
Tris-Hcl pH 7, 750mM NaCl, 10mM EDTA pH8, 1% SDS, 15%
forfamide, protease inhibitors) supplemented freshly by 1mM of
PMSF and Superase-in, and separated into two tubes for the two
pools of probes (Odd and Even). Probes were added at 100 pmol
probe/mL of initial lysate (before hybridization buffer) and incu-
bated for 4 h at 37◦C. After washing the C-1 magnetic beads
(Invitrogen) twice with lysis buffer, beads were added into the
lysate for 1h at 37◦C (100µL beads/mL initial lysate). Beads were
then washed five times by shaking for 5min at 37◦C in pre-
warmed washing buffer (2× Saline Sodium Citrate (SSC) 0.5%
SDS, proteases inhibitors) supplemented by fresh 1mM PMSF and
Superase-in. After the last wash, beads were resuspended in 1mL
of washing buffer and separated for DNA and RNA purification
as described in ChIP.
CHROMATIN PRECIPITATION (ChIP)
Cells were washed twice with PBS and then trypsinized at RT for
5min. Cells were then washed twice with PBS, cross-linked at
4◦C for 10min in 400µL 1% paraformaldehyde/PBS and then
quenched by 400µL cold glycine at 250mM (final concentra-
tion 125mM) for 5min at 4◦C. After centrifugation at 4◦C for
5min at 2500 rcf, pellets were resuspended in 250µL of lysis
buffer [50mM HEPES-KOH pH 7.5, 140mM NaCl, 5mM EDTA
pH8, 1% Triton-X100, 0.5% NP-40, 0.5mM DTT, 1% SDS, pro-
tease inhibitors (Roche)] for 10min on ice with occasional shaking.
Chromatin fragmentation was done by two sonication cycles
(water bath-sonicator) of 10min (output 7) with 1min break on
ice between. Lysate was cleared by centrifugation at 20,000× g for
10min and supernatant was stored at−80◦C if needed. Lysate was
incubated at 65◦C for 1.5 h to reverse the cross-linking and kept
for total mRNA and total protein extraction. Forty micro litter
of protein G magnetic beads (Cell Signaling®) were washed twice
with SDS free RIPA buffer (50mM Tris-HCl pH8, 150mM NaCl,
2mM EDTA pH8, 1% NP-40, 0.5% sodium deoxycholate, protease
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inhibitors) and incubated for 1 h at 4◦C in SDS-free RIPA buffer
with 0.1µg/µL BSA (New England biolabs) and 75 ng/µL ssDNA
(Salmon sperm DNA, Invitrogen). Finally, beads were washed
with SDS free RIPA buffer and resuspended in SDS free RIPA
buffer with 0.1µg/µL BSA and 75 ng/µL ssDNA. Remaining
lysate was also diluted in the previous solution up to 1mL with
10µL of ChIP-grade anti-mH2A1 antibody (ab37264, Abcam)
for 1 h at 4◦C. Prepared beads were then added in tubes and incu-
bated overnight at 4◦C. Beads were captured on magnetic rack
and wash three times at 4◦C with RIPA/SDS (20mM Tris-HCl
pH8, 150mMNaCl, 2mMEDTA pH8, 1% triton-X100, 0.1% SDS)
and then three times at 4◦C with high stringency RIPA buffer
(20mM Tris-HCl pH7.5, 500mM NaCl, 2mM EDTA pH8, 1%
triton-X100, 0.1% SDS). Complexes were eluted from beads by
adding 60µL of elution buffer (100mM NaHCO3, 1% SDS) and
incubating at 30◦C for 20min. Beads were removed by capture
on the magnetic rack and supernatants were incubated at 65◦C
for 1.5 h to reverse the cross-linking. Samples were then divided
in three to analyze the DNA, RNA and protein contents.
ChIRP AND ChIP SAMPLES ANALYSIS
For protein analysis, 4× Laemmli sample buffer was added to
both input and immunoprecipited samples and boiled at 100◦C
for 10min before loading on a Nupage Novex 10% Bis-Tris gel
(Life Technologies®). Proteins were then transferred to a nitro-
cellulose membrane (Life Technologies®). Membranes were first
incubated for 1 h at room temperature with the Odyssey block-
ing buffer (LI-COR Biosciences®) and then incubated overnight
with primary antibodies diluted in Odyssey blocking buffer at
4◦C. After three washes of 10min with PBS-tween (0.05% Tween-
20), membranes were incubated with secondary anti-mouse
IRDye 680LT or anti-rabbit IRDye 800CW antibodies (LI-COR
Biosciences) diluted at 1:10,000 in PBS-tween for 1h at room
temperature in the dark. After, three final washes of 10min with
PBS-tween membranes were imaged using the Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE) according to
the manufacturer’s instructions.
For DNA purification, samples (input and purified) were first
incubated with RNAse A (1mg/mL) (Invitrogen®) at 37◦C for 2 h
in DNA elution buffer (50mM NaHCO3, 1% SDS). Supernatant
was then separated from beads, if necessary, and each sample
was incubated with 15µL of proteinase K at 50◦C for 45min.
Samples were then boiled at 95◦C for 10min and DNA frag-
ments were purified with PCR purification kit (Quiagen). PCR
was performed as described previously for cDNA.
For RNA purification, 10µL of RNA samples (input and puri-
fied) were first treated with proteinase K (5µL) in proteinase
K buffer (85µL) (10mM Tris-HCl pH 7, 100mM NaCl, 1mM
EDTA, 1% SDS) for 45min at 50◦C. Samples were boiled at 95◦C
for 10min and RNA was purified with RNeasy minikit (Quiagen)
and analysis was done as previously described.
ANTIBODIES
For western blot experiments, ChIP grade mH2A1 (Abcam,
ab37264), GAPDH (Abcam, ab9484), H2AK119Ub (Millipore,
#AB10029) and O-GlcNAc (RL2) (Thermoscientific,
MA1-072) antibodies were used at a dilution of 1:1000.
For immunofluorescence experiments, O-GlcNAc (RL2)
(Thermoscientific, MA1-072), OGT (TI14) (Sigma Aldrich,
O6014), RNA polymerase II (phospho S2) (Abcam, ab5095
and ab5408), RNA polymerase II (phospho S2/5) (Cell sig-
naling, #4735), Actin (Abcam, ab1801) and H3K27Me3
(Millipore, #07-449) antibodies were used at a dilution of 1:200,
mH2A1 (Cell signaling, #4827) and pan RNA polymerase II
(RBP8) (Abcam, ab169924) at a dilution of 1:100.
RESULTS
OGT IS SUBJECTED TO X-INACTIVATION TO MAINTAIN OGT
TRANSCRIPT LEVELS
We first investigated OGT expression in different human fibrob-
last cell lines: GM00254 (XXX, triple-X female), GM00468 (XY-
male) and GM06111 (XX-female). In these XX and XXX cell
lines, X-inactivation has occurred and follows the normal X-
inactivation n-1 rule (Lyon, 1996; Lee and Jaenisch, 1997): only
one X-chromosome is activated per cell, the others are inacti-
vated (Figure 1A). X-inactivation status was determined by the
expression of XIST lncRNA and, as expected, male (XY) had
lower levels of XIST lncRNA relative to female (XX) cells that
have undergone X-inactivation (Figure 1B). Moreover, XIST lev-
els increased further in triple-X female (XXX), which have two
inactivated X-chromosomes. Levels of OGT mRNA did not differ
in male, female or triple-X cells despite the increased copy num-
ber ofOGT in these cell lines (Figure 1B). Next, male, female and
triple-X female human fibroblasts were subjected to 5-azacytidine
treatment. This cytidine analog blocks DNA methyltransferase
thereby decreasing DNA methylation, which is partly responsible
for Xi-silencing. Without the addition of 5-azacytidine (−), the
different cell lines showed the same pattern observed by classic
RT-PCR (Figure 1C). 5-azacytidine treatment (+) did not affect
OGT expression in male cells (XY), consistent with the absence
of X-inactivation. In contrast, female cells and triple-X cells’OGT
expression increased by ∼2 and 3 fold relative to OGT expression
before 5-azacytidine treatment, respectively. These data are con-
sistent with the presence of two and three copies of OGT alleles in
female and triple-X female cells. Interestingly, the relative expres-
sion of XIST is also greatly reduced after 5-azacytidine treatment
in female and triple-X female cells (Figure 1D).
Because 5-azacytidine affects genome-wide DNA methyla-
tion and not only X-chromosome silencing, we investigated
X-inactivation by using RNA interference against XIST mRNA.
Similar to the addition of 5-azacytidine, male cells were not
affected by XIST RNAi treatment (+) in comparison to con-
trol RNAi (−) (Figures 1E,F). Knocking-down XIST expression
led to significant increases in relative OGT expression in female
and triple-X cells (Figure 1E). The efficiency of the RNAi trans-
fection was confirmed by a decrease of XIST RNA expression
(Figure 1F). Taken together, these results suggest that the OGT
locus is silenced by X-inactivation.
We next hypothesized that one allele of OGT is transcribed
in each cell and that additional OGT alleles are associated with
major components of the Barr body, such as XIST RNA and
mH2A1. To determine the transcriptional status of OGT, we
observed the localization of the OGT primary transcript in
comparison to XIST lncRNA by RNA-FISH. The OGT primary
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FIGURE 1 | OGT is subject to X-inactivation in females. (A) Male
(GM00468), Female (GM6111) and triple-X (GM00254) human fibroblasts
show different X-inactivation profiles: no Xi in male, one Xi in female and 2 Xi
in triple-X female cells. (B) XIST mRNA expression, analyzed by RT-PCR, is
increased with Xi status. OGT expression remains the same in the different
cell lines. (C) 5-azacytidine, a DNA methylation inhibitor, increases OGT
mRNA expression according to the number of Xi, analyzed by qRT-PCR and
performed in triplicate. (D) XIST mRNA expression is decreased in the
presence of 5-azacytidine, showing the decrease in components required for
X-inactivation. (E) XIST RNAi treatment also increases OGT mRNA
expression according to the number of Xi in these human fibroblasts as
detected by qRT-PCR performed in triplicate. (F) Efficiency of XIST RNAi was
confirmed by a decrease in XIST mRNA expression by qRT-PCR. NS: P > 0.1;
∗0.1 > P > 0.01; ∗∗0.01 > P > 0.001; ∗∗∗0.001 > P > 0.0001; ∗∗∗∗0.0001 > P.
transcript was detected using an intronic probe. We observed that
XIST lncRNA spreads along the inactive X (Xi), and were able
to observe 0, 1 or 2 spots in male, female and triple-X female
(Figure 2A), respectively. In contrast, OGT primary transcript
was only synthesized by the active X (Xa), and was synthe-
sized by only one X-chromosome in male female or triple-X
female (Figure 2A). As a positive control, PPIB [Bos Taurus
Peptidylprolyl Isomerase B (cyclophilin B)] and RNA polymerase
II mRNA were localized throughout the cells (Figure S1A). As a
negative control, we were unable to detect bacterial DNA using
2 probes in these human cells (Figure S1A). This experiment
confirms that OGT is synthesized only from one chromosome in
these cell lines and that additional OGT alleles are silenced by the
spread of XIST lncRNA.
In order to determine if OGT is associated with components
of the Barr body, we performed Chromatin-Isolation by RNA
Purification (ChIRP) of XIST lncRNA inmale, female, and triple-
X female cells. The ChIRP assay pulls down specific RNA via
biotinylated probes after cross-linking. ThemRNA/DNA contents
were then investigated in total or purified extracts for each cell line
(Figure 2B). With the two sets of XIST RNA probes, serving as a
control for each other, XIST RNA was pulled-down along with
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FIGURE 2 | OGT is expressed from Xa and extra-OGT alleles are part
of the X-inactivation complex. (A) RNA-FISH analysis of the OGT
primary transcript and XIST lncRNA in male, female and triple-X female
cells indicates that OGT expression does not co-localize with the Xist
lncRNA. Xa: active X-chromosome; Xi: inactive X-chromosome. (B)
Chromatin isolation by RNA Purification (ChIRP) of XIST RNA, a major
component of Barr body, shows interaction of the OGT locus with XIST
mRNA. As a control, G6PD, another X-linked gene is also found to
interact, but not SRY, which is on the Y chromosome. (C)
Chromatin-Immunoprecipitation of mH2A1, another key component of the
Barr body demonstrates interactions with the OGT gene and XIST
mRNA. (D) Chromatin-Immunoprecipitation of mH2A1 also demonstrates
that no O-GlcNAcylated proteins are associated with the
immuno-precipitated complexes.
G6PD (Glucose-6-phosphate dehydrogenase), a well-known X-
inactivated gene (Xq27) (Szabo et al., 1984; Martini et al., 1986).
XIST was specifically amplified using primers that spanned exon-
exon junctions. G6PD gene was identified by PCR using intronic
primers. As a control, we did not find detect the SRY gene, which
is on the Y chromosome, except in the male input condition.
As expected, we also pulled down the OGT gene, using specific
intronic primers, with both sets of probes, indicating that the
OGT locus is associated with XIST RNA cells (Figure 2B).
We then performed a Chromatin-Immunoprecipitation
(ChIP) followed by RT-PCR or PCR, using an mH2A1antibody,
as another representative component of the Barr body (Mermoud
et al., 1999). Protein, mRNA and DNA contents were investigated
in total or as immunoprecipitated extracts for each cell line
(Figures 2C,D). As expected, we found mH2A1 in association
with the XIST lncRNA as well as OGT DNA (Figure 2C). By
protein analysis, we showed that ubiquitinylated lysine 119
of histone H2A (H2AK119Ub) co-immunoprecipitated, but
not the negative control GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) (Figure 2D).
These biochemical experiments confirmed that theOGT locus
is part of an X-inactivation complex, composed at least of XIST
lncRNA, mH2A1 and H2AK119Ub (Figures 2C,D). Although
we were able to detect other proteins that immunoprecipatated
with mH2A1 by coomassie blue staining, we found very few
O-GlcNAcylated proteins associated with the Barr body purifica-
tion (Figure 2D). This finding was unexpected given the literature
linking O-GlcNAc cycling to PcG proteins and Polycomb repres-
sion in mammals. Polycomb repression is known to play a key
role in X-inactivation leading to extensive compaction to form
the highly heterochromatinized Barr body. To better understand
our findings, we investigated whether OGT andO-GlcNAc targets
were present in the Barr body.
THE BARR BODY IS ENRICHED FOR REPRESSIVE EPIGENETIC MARKS
BUT DEPLETED OF O-GLcNAc AND OGT
Previous studies have shown that O-GlcNAc is an abundant
modification in interphase nuclei, and found highly concen-
trated at nuclear pores and subdomains within the nucleus
(Hanover, 2001). Similarly, we detected an intranuclear distri-
bution of OGT (Figure 3). We sought to determine whether
O-GlcNAc might be associated with Barr bodies. The Barr body
is known to have a unique chromatin signature maintained
by excluding some chromatin modifiers while enriching others
(Chadwick and Willard, 2003). Morphological inspection of the
Barr body in interphase nuclei has proven to be a useful tool
in order to look at numerous chromatin modifications includ-
ing methylation and acetylation (Chadwick and Willard, 2003).
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FIGURE 3 | Barr bodies do not require O-GlcNAc cycling. (A) A
strong-DAPI staining signal and/or a lack of elongating RNA polymerase II
(PhosphoS2) signal were used to localize Barr bodies (white arrows).
O-GlcNAc staining is largely excluded from Barr body. (B) OGT is also less
intense in Barr body. (C) Unlike elongating RNA polymerase II (PhosphoS2),
unmodified RNA polymerase II co-localized with the Barr body. (D) Barr
bodies were identified as in this figure. H3K27me3 strongly co-localized with
Barr bodies, suggesting a highly silenced region. (E) mH2A1 also co-localized
with Barr bodies. In both experiments, O-GlcNAc staining did not co-localize
with these Barr body-specific staining regions. (F) RNA-FISH analysis of the
OGT primary transcript and XIST lncRNA in female and triple-X female, in
presence of azaserine of Thiamet G. Xa: active X-chromosome; Xi: inactive
X-chromosome. Immunofluorescence pictures are representative of triplicate
experiments.
To identify the Barr body, we initially looked for the exclusion
of elongating RNA polymerase II (phospho-S2) staining on the
periphery of the nucleus. With immunostaining of elongating
RNA polymerase II, we identified 0, 1 or 2 Barr bodies in male
(XY), female (XX) and triple-X (XXX) human fibroblasts, respec-
tively (Figures 3A,B; white arrows). The identified Barr bodies
were also DAPI-rich as it has been reported (Peters et al., 2002),
likely due to an increased amount of chromatin compaction of
heterochromatin. Surprisingly, the Barr bodies lacked staining of
O-GlcNAcylation (Figure 3A) and OGT (Figure 3B). In order to
demonstrate that the exclusion of O-GlcNAcylation was not due
to an artifact of a specific antibody, we confirmed the exclusion
using another phospho-S RNA polymerase II antibody (phospho
S2/5) (Figure S1B). Single secondary antibody staining also con-
firmed the specificity of observed signals (Figure S1C). However,
unphosphorylated RNA polymerase II colocalized with the Barr
bodies (Figure 3C), which were identified in this set of exper-
iments by both a lack of O-GlcNAc staining and strong DAPI
staining. Together, these data show that the Barr bodies exclude
only the elongating form of RNA polymerase II. Exclusion of
O-GlcNAc from the inactive X was confirmed by comparing O-
GlcNAc staining with H3K27Me3 and mH2A1 staining, both
highly enriched in the Barr body (Figures 3E,F).
Because O-GlcNAc seems to be largely excluded from the Xi/
Barr body, we next hypothesized that modulation of O-GlcNAc
probably would not likely alter X-inactivation or Barr body
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formation. We examined the in situ staining of the OGT
primary transcript in comparison to XIST lncRNA by RNA-
FISH in presence of Thiamet G or azaserine (Figure 3F).
Thiamet G is an OGA inhibitor and increases O-GlcNAc lev-
els (Figure S1D). Azaserine inhibits GFAT (Glutamine fructose-
6-phosphate amidotransferase), a key enzyme of the HBP,
thereby decreasing UDP-GlcNAc levels and O-GlcNAcylation
(Figure S1D). In both conditions, and in both female and triple-X
female, modulating O-GlcNAcylation does not effect the local-
ization of the OGT primary transcript in relation to XIST
(Figures 2A, 3F). Taken together, this result suggests that O-
GlcNAc cycling is not required for X-inactivation or Barr body
formation.
DISCUSSION
The presence of mammalian OGT on the X-chromosome has
raised the question as to whether it is silenced or escapes
X-inactivation. In fact, OGT is located close to the X-
inactivation center (XIC) (Brown et al., 1991; Shafi et al., 2000;
Hanover, 2001), suggesting a highly silenced location (Figure 4).
Whereas previous studies have indicated that Ogt is subject
to X-inactivation in mice (Lin et al., 2007), its transcriptional
status remained largely unknown in humans. Because many
more X-genes escape X-inactivation (15%) in humans than in
mice (3%) (Carrel and Willard, 2005; Yang et al., 2010) it
remained imperative to investigate OGT gene dosage in human
cells. Here, we definitively show that indeed OGT is sub-
ject to X-inactivation in humans. Importantly, understanding
regulation of OGT provides insights into human diseases in
which aberrantO-GlcNAcylation has been correlated with disease
progression.
In this study, we demonstrate that additional alleles of OGT
are silenced in human female cells. We show that the OGT gene
is subjected to X-inactivation in human fibroblasts to main-
tain near constant levels of OGT independent of X-chromosome
number. As a consequence, OGT expression is equal in male,
female or triple-X female cells. These three cell lines have 1,
2 or 3 X chromosomes, respectively, and only one should
be active, with the remaining X-chromosomes inactivated. We
demonstrated that the OGT locus co-immunoprecipitated with
XIST lncRNA, mH2A1 and ubiquitinylated lysine 119 of his-
tone H2A, key components of X-inactivation process and of
the Barr body, suggesting that OGT is potentially subject to X-
inactivation. Additionally, we have demonstrated that removal
of DNA methylation triggers derepression of OGT in female
and triple-X female cells. In the same manner, knock down
of XIST lncRNA, increased OGT expression, further demon-
strating X-inactivation-dependent repression of OGT. Moreover,
we also showed that the OGT primary transcript does not co-
localized with XIST lncRNA-coated chromosomes. Analysis of
DNA encoding OGT indicated association with X-inactivation
complex members, such as as mH2A1, and XIST lncRNA,
FIGURE 4 | OGT expression is regulated by X-inactivation in
female mammals. The X-inactivation process begins with a
counting/choice of which chromosome to inactivate. X-inactivation
leads to silencing of almost the entire X-chromosome, including the
XIST -proximal OGT gene, by recruitment of polycomb group proteins
via XIST lncRNA and appearance of DNA repressive marks such as
H3K27me3, H2AK119Ub and mH2A1. Once inactivation is completed,
the inactivated X-chromosome (Xi) is re-localized in a highly
compacted structure called the Barr body, from which OGT protein
and O-GlcNAcylation are largely excluded indicating a highly
transcriptionally silenced region. This process allows the dosage of
OGT protein to be normalized in expression independent of the
number of X-chromosomes. Escape from X-inactivation can lead to
increases in OGT expression. Xa: active X-chromosome.
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Taken together, these findings show that OGT is subject to
X-inactivation and raise many questions about whether OGT
reactivation may be implicated in diseases that show a gender bias
preferentially affecting females. We have suggested that OGT may
be one of the X-linked genes serving as a driver of diseases involv-
ing chromosome imbalance (Abramowitz et al., 2014; Olivier-Van
Stichelen et al., 2014).
In fact, aberrant methylation levels have been implicated in
lupus development. Interestingly, this autoimmune disease has
a higher prevalence in females and Klinefelter syndrome males
(XXY), both of whom have 2 X-chromosomes, than in normal
males. It has been suggested that demethylation of the silenced
X-chromosome causes re-expression of many X-linked genes,
including OGT, in these patients (Hewagama et al., 2013). These
authors have posited that the increased OGT expression and
O-GlcNAcylation level, may trigger or worsen lupus develop-
ment (Hewagama et al., 2013). Moreover, deregulation of the
X-inactivation process is also involved in human cancer develop-
ment, often through methylation defects causing reactivation of
silenced genes (Karpf and Jones, 2002; Liao et al., 2003; Pageau
et al., 2007). Indeed, many cancers have been identified to have
increased O-GlcNAc levels (Fardini et al., 2012). Moreover, mul-
tiple female-associated cancers, like breast and endometrial, have
increased OGT and/or O-GlcNAc levels (Slawson et al., 2001; Gu
et al., 2010; Krzes´lak et al., 2012; Champattanachai et al., 2013).
Even if other non-gender specific cancers also have increased O-
GlcNAcylation (Fardini et al., 2012), reactivation of Xi in female
could potentially worsen or accelerate the process in the female
patient.
In a second set of experiments, we endeavored to determine
whether OGT and O-GlcNAcylation could be involved in the
X-inactivation process itself. Indeed, O-GlcNAcylation has been
found associated with chromatin preparations (Kelly and Hart,
1989), on transcription factors (Ozcan et al., 2010), on RNA
polymerase II (Comer and Hart, 2001; Ranuncolo et al., 2012),
and on histones H2A, H2B, H3, and H4 (Sakabe et al., 2010).
Our lab has also shown that O-GlcNAcylation is particularly
abundant on the promoter region in C. elegans (Love et al.,
2010). Furthermore, OGT is also associated with TET (Ten-
Elevent Translocation) proteins, responsible for demethylation
of DNA and activation of transcription (Mariappa et al., 2013).
Taken together, these studies implicate O-GlcNAcylation in chro-
matin remodeling and gene regulation, important features for
X-inactivation.
In this study, we demonstrate that the Barr body, hosting
the inactivated X-chromosome, is almost entirely devoid of O-
GlcNAcylation. Moreover, OGT is also largely excluded from
this perinuclear structure. During the X-inactivation process, Xi
acquires silenced histone marks like trimethylated lysine 27 of
histone 3, ubiquitinylated lysine 119 of histone 2A and mH2A1
(Mermoud et al., 1999; Plath et al., 2003; De Napoles et al., 2004).
By this process, Xi is transformed to an ultra-condensed chro-
matin structure and we have demonstrated that it almost com-
pletely excludes O-GlcNAcylation and OGT. By definition, this
structure also excludes the elongating form of RNA polymerase II
(Phospho-S), although we show non-elongating RNA polymerase
II in this region by pan RNA polymerase II antibody staining. As
previously demonstrated, RNA polymerase II is O-GlcNAcylated
on the C-terminal domain andO-GlcNAcylated RNA polymerase
II is a transient state during the initiation complex formation
(Ranuncolo et al., 2012). O-GlcNAcylation of RNA polymerase
II is thought to occur in pre-initiation state before CTD kinases
may act. In the case of a silenced Barr body, it is intriguing
that of O-GlcNAcylation and RNA polymerase II do not colo-
calize in this completely silenced region of DNA. The absence
of O-GlcNAcylation also corresponded with strong DNA inac-
tivation marks, such as mH2A1, H3K27Me3 and H2AK119Ub.
Consequently, the Barr bodies were neither enriched in O-
GlcNAcylation nor OGT suggesting that the RNA polymerase II
present there is not heavily O-GlcNAc modified in the Barr body.
Furthermore, O-GlcNAcylation modulation does not effect the
Xa/Xi distribution, confirming that X-inactivation and Barr body
formation does not require O-GlcNAc cycling. This finding is
consistent with a role for OGT andO-GlcNAcylation in transcrip-
tion initiation, as phosphorylated isoforms of RNA polymerase II
are also excluded from the Barr body.
The data presented herein support that randomX-inactivation
in adult female cells silences all but one of theOGT alleles leading
to normalized gene expression (Figure 4). This process is distinct
from the imprinted X-inactivation that occurs in the trophoblast
where OGT sometimes escapes inactivation (Reviewed in Olivier-
Van Stichelen et al., 2014). X-inactivation in the human female
involves a multistep process involving an X-chromosome count-
ing mechanism, choice of Xa/Xi and subsequent X-inactivation.
The creation of a condensed structure isolates the Xi and the
extra-OGT allele in a peri-nuclear area. Consequently, OGT lev-
els are maintained independently of X-chromosome number.
Intriguingly, OGT and O-GlcNAcylation are mostly excluded in
the Barr body as detected by immunofluorescence and chro-
mosome immunoprecipitation. This observation supports a role
for OGT and O-GlcNAcylation in transcription initiation rather
than silencing of DNA, although X-inactivation is known to
require polycomb group complexes PRC2, which may associate
with OGT (Myers et al., 2011; Chu et al., 2014). Nevertheless,
O-GlcNAcylation may act upstream of Barr body formation to
regulate the PRC2 complex. Thus, our findings suggest that while
O-GlcNAc cycling may play a role in PRC2 function leading to
X-inactivation, high levels ofO-GlcNAc are not required to main-
tain the strong transcriptional repression necessary for silencing
in the Xi/Barr body.
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Figure S1 | Barr bodies exclude O-GlcNAcylated proteins and elongating
RNA polymerase II (phospho S2/5). (A) RNA-FISH specificity is confirmed
by positive and negative control sets, using PPIB/ RNA pol II mRNA and
Bacterial mRNA probes, respectively. (B) An additional elongating RNA
polymerase II (phospho S2/5) antibody confirms the exclusion of
O-GlcNAcylation from Barr Bodies. (C) Fluorescent secondary antibodies
alone show the specificity of primary antibodies used in this study. (D)
Efficiency of Thiamet G and azaserine is demonstrated respectively by
increased of decreased staining of O-GlcNAc antibody.
Immunofluorescence pictures are representative of triplicate experiments.
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